NextCell Pharma Q3 2024/2025: Largely as expected - Redeye

Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations. While 2025 has been a turbulent year so far, the storm is now largely weathered. With a modest valuation and secured funding that covers upcoming potential value inflection points, we reiterate our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1119079/nextcell-pharma-q3-2024-2025-largely-as-expected?utm_source=finwire&utm_medium=RSS